Pfizer Inc. PFE
Composite 49/100; the shares have moved about 21% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 29/100 — a moderate mark against it.
Income ranks 93/100 — a strong point in its favour. Momentum ranks 63/100 — a moderate point in its favour.
Growth ranks 29/100 — a moderate mark against it. Valuation ranks 44/100 — a slight mark against it. Balance-sheet strength ranks 45/100 — a slight mark against it.
What the company does Pfizer discovers, develops, manufactures, and markets biopharmaceuticals across multiple therapeutic areas including internal medicine, vaccines, oncology, inflammation, rare diseases, and anti-infectives. Its portfolio features blockbusters like Eliquis, Prevnar, and Paxlovid, alongside newer products such as Nurtec ODT/Vydura and Zavzpret for migraine.
Key financials Pfizer’s trailing P/E is 34.81 with a forward P/E of 9.17; EV/EBITDA stands at 15.24. Margins are mixed: gross 74.7%, operating 27.9%, net 6.8%. ROE is 5.0%, ROA 5.8%, and ROCE 4.1%. Revenue and EPS growth are negative at -1.7% and -3.5%, respectively. Dividend yield is 6.1% with a 56.4% payout ratio.
Stock health SiderAvia scores Pfizer weak overall (48.9/100), with Quality 49.4 and Growth 33.2. Momentum is elevated (RSI 77.40), with 12-month return of 20.54%. The Piotroski F-Score is 6/9 and Altman Z is 2.05, indicating moderate financial health.
Price vs fair value Pfizer’s price trades at a discount of 1.40% versus the analyst mean target of 28.64. - Fresh legal questions raise valuation questions (Simply Wall St.) - BioNTech’s cancer vaccine win spurred sector rotation away from legacy players (Barrons.com) - Comparisons to Merck and Amgen highlight relative underperformance in 2026 (24/7 Wall St.)
Looking forward Forward earnings multiple compression to 9.17x suggests expectations for margin normalization or patent pressures. Legal and competitive dynamics remain key swing factors for near-term valuation.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.